Atrial fibrillation has become a serious health problem. According to Professor Phillippe from France, based on a survey in five European countries, repeated hospitalizations and interventions for atrial fibrillation are the main cause of increased costs of atrial fibrillation treatment, exceeding 70% of the total hospitalization costs. In Europe, hospitalizations for stroke due to AF account for 1/5 of all stroke patients. Both the Framingham study in the US and the Manitoba study in Canada showed that mortality in patients with AF was nearly twice as high as in non-AF patients and that AF resulted in significantly higher rates of stroke, heart failure, rehospitalization, and exercise limitation in patients with AF. The risk of ischemic stroke is five times greater in patients with AF than in those without AF, and the incidence of stroke increases significantly with age, with the annual prevalence increasing from 1.5% in patients aged 50-59 years to 23.5% in patients aged 80-89 years (Lioyd-Jones D, et al. Circulation. 2009; 119: 480-6). Stroke is not reduced by ventricular rate control in atrial fibrillation. Paulus K highlighted the ACTIVE study: although the ACTIVE W study showed that the combination of clopidogrel and aspirin was inferior to oral anticoagulants in patients at intermediate and high risk of stroke, ACTIVE A showed that in patients with atrial fibrillation with a CHADS2 score above and including 1, the results showed that the combination of clopidogrel and aspirin was effective in preventing the vascular The results showed that the combination of clopidogrel and aspirin was effective in preventing the risk of vascular events, especially stroke, in AF. In patients with atrial fibrillation who are unable to take oral warfarin, clopidogrel in combination with aspirin is a more effective treatment option than aspirin. The combination of clopidogrel and aspirin significantly reduced major vascular events by 11% (p=0.014) and the benefit lasted for more than 4 years. The largest benefit was a 28% reduction in the relative risk of stroke (p